Optimal control for a stochastic model of cancer chemotherapy

Mathematical Biosciences

Volumn 168, Issue 2, 2000, Pages 187-200

  Coldman, Andrew J ^a   Murray, J M ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast cancer; Chemotherapy; Optimal control; Stochastic

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; MATHEMATICAL ANALYSIS; STOCHASTIC MODEL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMPUTER SIMULATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MODELS, BIOLOGICAL; STOCHASTIC PROCESSES;

EID: 0033668527     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-5564(00)00045-6     Document Type: Article

References (26)

1. Principles of chemotherapy
2. Biochemical and cell kinetic aspects of drug resistance
3. Mutations of bacteria from virus sensitivity to virus resistance
4. Genetic basis of drug resistance in mammalian cells
5. The origin of mutants
6. A model for the resistance of tumor cells to cancer chemotherapeutic agents
7. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy
8. Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency
9. Optimal control applications in biomedical engineering - A survey
10. Reduction of cytotoxicity to normal tissues by new regimes of cell cycle phase specific drugs
11. Low-intensity combination chemotherapy maximizes host survival time for tumors containing drug-resistant cells
12. Varieties of stochastic model: A comparative study of the Gompertz effect
13. Dynamics of normal growth
14. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo
15. The median lethal dose and its estimation
16. Experimental evaluation of anticancer agents. XIII. On the criteria and kinetics associated with curability of experimental leukemia
17. Sequential or alternating Doxorubicin and CMF regimens in breast cancer with more then 3 positive nodes, Ten year results
18. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer: The results of twenty years follow-up
19. Patterns of relapse and survival in operable breast carcinoma with positive and negative axillary nodes
20. A simplex method for functional minimization
21. Tumor size, sensitivity to therapy, and design of treatment schedules